Omnicell (NASDAQ:OMCL) Releases FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its FY 2025 earnings guidance on Saturday morning. The company provided earnings per share (EPS) guidance of 1.000-1.650 for the period, compared to the consensus estimate of 1.770. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion.

Omnicell Stock Performance

Shares of OMCL stock opened at $27.96 on Friday. The stock has a market cap of $1.31 billion, a P/E ratio of 103.56, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The company has a fifty day moving average price of $31.41 and a two-hundred day moving average price of $39.46. Omnicell has a one year low of $22.66 and a one year high of $55.75.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The company had revenue of $269.67 million during the quarter, compared to analysts’ expectations of $260.18 million. During the same quarter last year, the company posted $0.03 EPS. Omnicell’s quarterly revenue was up 9.5% compared to the same quarter last year. As a group, equities analysts predict that Omnicell will post 1.09 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. dropped their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Wells Fargo & Company upgraded shares of Omnicell from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $31.00 to $35.00 in a research note on Wednesday. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, May 3rd. Finally, Benchmark cut their price target on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Omnicell has a consensus rating of “Hold” and a consensus target price of $46.50.

Hedge Funds Weigh In On Omnicell

A hedge fund recently raised its stake in Omnicell stock. Empowered Funds LLC increased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 14.3% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 9,953 shares of the company’s stock after buying an additional 1,243 shares during the quarter. Empowered Funds LLC’s holdings in Omnicell were worth $348,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.